Brightsurf Science News & Current Events

October 20, 2018
Bioelectronic medicine treatment effective for lupus, pilot clinical trial shows
Results shared at ACR/ARHP annual meeting highlight non-invasive therapy reduces pain and fatigue associated with lupus.

Heart patients advised to move around every 20 minutes to prolong life
Heart patients are being advised to move around every 20 minutes in a bid to prolong life following a study presented at the Canadian Cardiovascular Congress (CCC) 2018.

Immune therapy generates promising results in hard-to-treat ankylosing spondylitis
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis (AS), a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.

First immunotherapy success for triple-negative breast cancer
New research led by Queen Mary University of London and St Bartholomew's Hospital has shown that by using a combination of immunotherapy and chemotherapy the body's own immune system can be tuned to attack triple-negative breast cancer, extending survival

Genetic study improves lifespan predictions and scientific understanding of aging
By studying the effect of genetic variations on lifespan across the human genome, researchers have devised a way to estimate whether an individual can expect to live longer or shorter than average, and have advanced scientific understanding of the diseases and cellular pathways involved in aging.

Barriers to early clinical trial access for adolescents and young adults still exist
Young cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse.

New, large sequence panel enables population genetics research in Africa
Geneticists have assembled the largest sets of African genomic data available to date, creating a resource that will help researchers understand the genetic structure of Africa as well as the effects of genetic variation on protein function and disease.

High stroke impact in low- and middle-income countries examined at 11th World Stroke Congress
Less wealthy countries struggle to meet greater need with far fewer resources.

Some patients with metastatic triple negative breast cancer live longer with immunotherapy
Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

New option for women with advanced breast cancer resistant to hormone therapy
Treatment with the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

Origami, 3D printing merge to make complex structures in one shot
By merging the ancient art of origami with 21st century technology, researchers have created a one-step approach to fabricating complex origami structures whose light weight, expandability, and strength could have applications in everything from biomedical devices to equipment used in space exploration.

Drugs for treating breast cancer in women are effective and well tolerated in men
There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

Treatment of aggressive breast cancer improved by immunotherapy-chemotherapy combination
Progression free survival in triple-negative breast cancer increased when immunotherapy-chemotherapy treatment combination is used as the first treatment option.

Major trial shows targeted drug extends breast cancer survival
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.